Drug
Bitopertin clinical trials
Also written RO4917838 and DISC-1459.
- studies test it
- 28
- open now
- 1
- in phase 3
- 8
- first study started
- 2005
Keep track of what changes. Save the bitopertin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
28 studies that test it; most in 2011 (8)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 7 |
| 2011 | 8 |
| 2012 | 3 |
| 2014 | 1 |
| 2017 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 7
- Phase 3
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 26 · Other 2
Hoffmann-La Roche (23) · Disc Medicine, Inc (3) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Wake Forest University Health Sciences (1)
Often tested with
Tested in the same studies.
RO4927838 (1) · Valproic Acid (1) · Carbamazepine (1) · Rosuvastatin (1) · Midazolam (1)
Studies
Open first, then newest update. How each study uses bitopertin is read from its arms, and is right about nine times in ten.
Testing it · 28
- HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLPEnrolling by invitationPhase 2/3Disc Medicine, IncNCT05883748Written as DISC-1459
- Study of Bitopertin in Participants With EPP or XLP (APOLLO)CompletedPhase 3Disc Medicine, IncNCT06910358Written as DISC-1459
- Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan AnemiaCompletedPhase 1/2National Heart, Lung, and Blood Institute (NHLBI)NCT05828108Written as Bitopertin
- Effect of Bitopertin on the Liver and on Levels of Protoporphyrin IX in Bile, Blood, Liver, and Stool in Patients With Erythropoietic Protoporphyria/X-linked Protoporphyria and Increased Liver Stiffness and/or Liver Enzymes at BaselineWithdrawnPhase 1Wake Forest University Health SciencesNCT07123363Written as bitopertin
- Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPPCompletedPhase 2Disc Medicine, IncNCT05308472Written as DISC-1459
- A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-ThalassemiaCompletedPhase 2Hoffmann-La RocheNCT03271541Written as Bitopertin
- A Study Exmining the Effect of Multiple Doses of Bitopertin on the Single Dose Pharmacokinetics of Midazolam in Healthy Volunteers.WithdrawnPhase 1Hoffmann-La RocheNCT02019290Written as bitopertin
- A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)CompletedPhase 2Hoffmann-La RocheNCT01674361Written as Bitopertin
- A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)CompletedPhase 3Hoffmann-La RocheNCT01192867Written as RO4917838
- A Pharmacodynamic and Pharmacokinetic Study of RO4917838 in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01543529Written as RO4917838
- A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of SchizophreniaCompletedPhase 3Hoffmann-La RocheNCT01192880Written as Bitopertin
- A Study of the Relative Bioavailability of Single Dose RO4917838 and the Effect of Food in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01665976Written as RO4917838
- A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective DisorderCompletedPhase 1Hoffmann-La RocheNCT01116830Written as RO4917838
- A Study of Bitopertin (RO4917838) in Healthy Male VolunteersCompletedPhase 1Hoffmann-La RocheNCT01636492Written as bitopertin
- A Study on the Effects of Valproate on the Pharmacokinetics of RO4917838 in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01495104Written as RO4917838
- A Study of the Effect of RO4917838 on the QTcF Interval in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01613040Written as RO4917838
- A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug UsersCompletedPhase 1Hoffmann-La RocheNCT01438749Written as RO4917838
- A Study on The Effect of Hepatic Impairment on The Pharmacokinetics of RO4917838CompletedPhase 1Hoffmann-La RocheNCT01356550Written as RO4917838
- A Study on the Effect of Renal Impairment on the Pharmacokinetics of RO4917838CompletedPhase 1Hoffmann-La RocheNCT01510899Written as RO4917838
- A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)CompletedPhase 3Hoffmann-La RocheNCT01235559Written as bitopertin [RO4917838] level 1
Codes
What other systems call bitopertin · ClinicalTrials.gg INT005664
- UNII (FDA) Q8L6AN59YYBITOPERTINConfirmed FDA, Wikidata
- Wikidata Q4918919bitopertinConfirmed FDA, Wikidata
- NCI Thesaurus C174879BitopertinOne source FDA
- DrugBank DB12426One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Q8L6AN59YY | BITOPERTIN | Confirmed FDA, Wikidata |
| Wikidata | Q4918919 | bitopertin | Confirmed FDA, Wikidata |
| NCI Thesaurus | C174879 | Bitopertin | One source FDA |
| DrugBank | DB12426 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.